<DOC>
	<DOCNO>NCT01474681</DOCNO>
	<brief_summary>This study design evaluate safety tolerability use HSC835 patient hematological malignancy .</brief_summary>
	<brief_title>Safety Tolerability HSC835 Patients With Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Patients diagnosis qualifies DUCBT Absence recent active mold infection Adequate organ function Availability eligible donor material Pregnancy breastfeed woman woman childbearing potential unless two acceptable form contraception use Human immunodeficiency virus ( HIV ) infection Active infection Extensive prior chemotherapy Prior myeloablative allotransplantation autologous transplant .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hematologic malignancy</keyword>
	<keyword>leukemia</keyword>
	<keyword>lymphoma</keyword>
</DOC>